A carregar...
Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients
BACKGROUND AND AIM: Tenofovir disoproxil fumarate (TDF) has been efficacious in treating chronic hepatitis B (CHB), but long‐term use is accompanied by a decline in renal function and bone mineral density (BMD). Tenofovir alefanamide (TAF) is a prodrug of tenofovir, with similar efficacy in CHB but...
Na minha lista:
| Publicado no: | JGH Open |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley Publishing Asia Pty Ltd
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7857293/ https://ncbi.nlm.nih.gov/pubmed/33553665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12481 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|